Summary by Moomoo AI
eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the announcement of its Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on August 1, 2024. The notice indicates that the company's submission, filed under the number 333-262339, has been reviewed and accepted by the SEC. This development is a key step in the regulatory process, allowing eFFECTOR Therapeutics to proceed with its planned activities as outlined in the submission type POS AM.
